What is it about?
Nras-mutated primary leptomeningeal melanomatosis in the era of targeted chemotherapy September 2015 - Journal of the Neurological Sciences 357(1):e181 DOI: 10.1016/j.jns.2015.08.623 Presented: At the XXII WCN World Cancer Congress. Santiago, Chile.
Featured Image
Photo by Marcelo Leal on Unsplash
Why is it important?
Quality of life + Impact of cancer + cancer therapy on the central and peripheral nervous system; Neurology needs to adapt the current practice to the reality of novel therapy.
Perspectives
Novel Therapies as Immunotherapy and Targeted TherapyTreatment/Management of Primary Brain Tumors.
Dr Catherine Maurice
University of Toronto
Read the Original
This page is a summary of: Nras-mutated primary leptomeningeal melanomatosis in the era of targeted chemotherapy, Journal of the Neurological Sciences, October 2015, Elsevier,
DOI: 10.1016/j.jns.2015.08.623.
You can read the full text:
Resources
ResearchGate
Conference Paper Nras-mutated primary leptomeningeal melanomatosis in the era of targeted chemotherapy M. Lim Fat, C. Maurice, R. Kiehl, R. Wennberg Journal of the Neurological Sciences, October 2015, Elsevier DOI: 10.1016/j.jns.2015.08.623
LinkedIn
Conference Paper: Nras-mutated primary leptomeningeal melanomatosis in the era of targeted chemotherapy M. Lim Fat, C. Maurice, R. Kiehl, R. Wennberg Journal of the Neurological Sciences, October 2015, Elsevier DOI: 10.1016/j.jns.2015.08.623
ORCID
Conference Paper: Nras-mutated primary leptomeningeal melanomatosis in the era of targeted chemotherapy M. Lim Fat, C. Maurice, R. Kiehl, R. Wennberg Journal of the Neurological Sciences, October 2015, Elsevier DOI: 10.1016/j.jns.2015.08.623
Contributors
The following have contributed to this page
